Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03581838
Other study ID # 18-002628
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 24, 2018
Est. completion date July 23, 2019

Study information

Verified date October 2019
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Is there a difference in the eating process for patients with active Eosinophilic Esophagitis (EoE) and those with inactive disease?


Description:

Eosinophilic esophagitis (EoE) patients develop adapted eating behaviors to prevent symptoms. These patients tend to cut their food small, chew extensively, take copious liquids with meals, and avoid foods that cause symptoms. No studies to date have directly evaluated these eating behaviors in patients with EoE with observation. Furthermore, none of the investigators' current metrics for patient symptom assessment visually evaluate the eating process nor are they compared before and after treatment. As a result, it is unclear if a patient's subjective perception of their eating difficulties and improvement matches with objective measures.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date July 23, 2019
Est. primary completion date July 23, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 18 years of age and older

- Patients suspected to have Eosinophilic Esophagitis

- Patients being treated for EoE with PPI or a steriod

- EoE patients that are in remission by having less than 22 on the EEsAI questionnaire

- Controls, patients that do not have EoE or other swallowing issues

Exclusion Criteria:

- Clinical evidence of infectious process potentially contributing to dysphagia (candidiasis, CMV,herpes)

- Other cause of dysphagia identified at endoscopy (reflux esophagitis, stricture, web, ring, achalasia, esophageal neoplasm)

- EoE patients that do not eat sandwiches or feel they could not eat a sandwich.

Study Design


Intervention

Behavioral:
Observed eating session
Eating a Jimmy Johns turkey or vegetarian sandwich

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Observed eating session number of bites of patient's with EoE and controls eating a Jimmy John's sandwich 15-90 minutes
Secondary Food slowness during eating session number of bites that felt stuck among patients with EoE and controls when eating a Jimmy John's sandwich 15-90 minutes
Secondary Water during eating session amount of water drank of patients with EoE and controls eating a Jimmy John's sandiwch 15-90 minutes
Secondary Eosinophilic Esophagitis activity Index (EEsAI) questionnaire The EEsAI Pro uses the VDQ is visual dysphagia question AMS is avoidance, modification, slow eating question . These two along with questions on frequency of, duration of, pain associated with dysphagia make up the PRO (patient reported outcomes). The PRO is a number (0-100) calculated from the answer to the questions. A PRO < 20 defines asymptomatic EoE. 10-15 minutes
Secondary Eosinophilic Esophagitis Quality of Life questionnaire Higher score denote better quality of life. 0-4 as follows 4=not at all, 3=Slightly 2=moderately, 1=Quite a bit, 0= Extremely 10-15 minutes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04394351 - Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) Phase 3
Terminated NCT03245840 - Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE) Phase 3
Completed NCT02778867 - SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Phase 2/Phase 3
Completed NCT01642212 - OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension Phase 2
Completed NCT05485779 - SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects Phase 1
Recruiting NCT04626609 - Prostaglandin and Cannabinoid Receptors in EoE
Completed NCT00762073 - Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis Phase 2
Terminated NCT02058537 - Bethanechol for Eosinophilic Esophagitis Phase 2
Completed NCT02605837 - A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved Phase 3
Completed NCT02320981 - Mucosal Impedance in Pediatric Population N/A
Recruiting NCT06389994 - Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy
Completed NCT02736409 - An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Phase 3

External Links